Education
About Us
Working with TipRanks
Follow Us
Cantargia AB (DE:7V3)
FRANKFURT:7V3
7V3 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.08 - €0.42
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€26.41M
Enterprise Value€256.35M
Total Cash (Recent Filing)€33.04M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Aug 21, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding248,611,650
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)1.84
Price to Sales (P/S)0.00
P/FCF Ratio-1.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Cantargia AB News
PremiumCompany Announcements
Cantargia’s CAN10 Antibody Shows Promise in Inhibiting Vascular Inflammation
PremiumCompany Announcements
Cantargia AB Announces Key Resolutions from Annual General Meeting
PremiumCompany Announcements
Cantargia AB’s Promising Interim Report for Early 2025
PremiumCompany Announcements
Cantargia’s CAN10 Achieves Promising Phase 1 Results, Sets Stage for Phase 2
PremiumCompany Announcements
Cantargia’s Nadunolimab Shows Promise in Solid Tumor Treatment
PremiumCompany Announcements
Cantargia’s Nadunolimab Shows Promise in Overcoming Cancer Immunosuppression
7V3 FAQ
What was Cantargia AB’s price range in the past 12 months?
Cantargia AB lowest stock price was €0.08 and its highest was €0.42 in the past 12 months.
What is Cantargia AB’s market cap?
Cantargia AB’s market cap is €26.41M.
When is Cantargia AB’s upcoming earnings report date?
Cantargia AB’s upcoming earnings report date is Aug 21, 2025 which is in 71 days.
How were Cantargia AB’s earnings last quarter?
Cantargia AB released its earnings results on May 13, 2025. The company reported -€0.017 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.017.
Is Cantargia AB overvalued?
According to Wall Street analysts Cantargia AB’s price is currently Overvalued.
Does Cantargia AB pay dividends?
Cantargia AB does not currently pay dividends.
What is Cantargia AB’s EPS estimate?
Cantargia AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cantargia AB have?
Cantargia AB has 248,611,650 shares outstanding.
What happened to Cantargia AB’s price movement after its last earnings report?
Cantargia AB reported an EPS of -€0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.333%.
Which hedge fund is a major shareholder of Cantargia AB?
Currently, no hedge funds are holding shares in DE:7V3
Company Description
Cantargia AB
Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system and is under phase IIa clinical trial; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis, and is under preclinical trial. It is also developing CANxx antibodies against IL1RAP. The company has collaboration agreements with Patheon Biologics BV and BioWa Inc. for the manufacture and production of CAN04; and Specialized Medical Services-oncology BV for the clinical study of CAN04. Cantargia AB (publ) was founded in 2010 and is based in Lund, Sweden.
Technical Analysis
Oncopeptides AB
―
Xbrane Biopharma AB
―
Isofol Medical AB
―
Guard Therapeutics International AB
―
Immunicum AB
―